

Are gut hormone changes the reason why the long-limb gastric bypass is more effective than the standard limb gastric bypass in improving type 2 diabetes mellitus?

Submission date 29/07/2015	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 30/07/2015	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
Last Edited 18/08/2023	Condition category Nutritional, Metabolic, Endocrine	<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Background and study aims

Obesity is the main cause of the world wide epidemic of diabetes. Weight loss, or bariatric, surgery produces major and sustained weight loss and is being increasingly used to treat obese diabetic patients. There was initial optimism that these procedures might cure all diabetes. However, the gold-standard operation, standard gastric bypass, effectively cures diabetes in only 4 out of 10 patients. To design a safer and more successful procedure we need to understand how bariatric surgery works to improve diabetes. Hormones from the gut are released when we eat food. They control how the body uses the food it absorbs. For example they release the sugar lowering hormone insulin, and also greatly reduce appetite, which is why one feels less hungry after eating a meal. We have discovered that the good effects of bariatric surgery, and in particular the gastric bypass, are mainly due to increased release of gut hormones, reducing patients appetite and improving the release of insulin. In this project we will be testing a new procedure called the long-limb gastric bypass. It is designed particularly to be better at helping the diabetes in overweight patients, while being as safe as the currently available standard gastric bypass. We now want to show that this new procedure works better than the standard gastric bypass by causing an even bigger increase in the release of gut hormones and therefore insulin.

Who can participate?

Obese adults (aged 18-70 years) with type 2 diabetes.

What does the study involve?

Participants are randomly assigned into one of two groups. Those in group 1 have a standard-limb gastric bypass. Those in group 2 have a long-limb gastric bypass. Using a newly developed technique (mass spectroscopy) we then measure the differences in gut hormone secretion between the new long-limb and the standard gastric bypass. We also use a well-tested insulin sensitivity procedure (glucose clamp), both to confirm and to investigate how and why each participants diabetes has improved after the surgery.

What are the possible benefits and risks of participating?

The measurements we will be making are non-invasive and safe. The only discomfort comes from inserting a cannula to take blood samples.

Where is the study run from?

Imperial College London, Hammersmith Hospital (lead centre) and King's College London (UK)

When is the study starting and how long is it expected to run for?

August 2015 to February 2018

Who is funding the study?

National Institute for Health Research (UK)

Who is the main contact?

Dr Alex Miras

Contact information

Type(s)

Public

Contact name

Dr Alex Miras

ORCID ID

<https://orcid.org/0000-0003-3830-3173>

Contact details

Hammersmith Hospital

Du Cane Road

London

United Kingdom

W12 0HS

Type(s)

Scientific

Contact name

Dr Belen Perez Pevida

Contact details

NIHR Imperial Clinical Research Facility

Imperial Centre for Translational and Experimental Medicine

Section of Investigative Medicine, Division of Diabetes, Endocrinology & Metabolism

Imperial College London

London

United Kingdom

W12 0NN

N/A

belen.pevida@nhs.net

Additional identifiers

Clinical Trials Information System (CTIS)

Nil known

ClinicalTrials.gov (NCT)

Nil known

Protocol serial number

19153

Study information

Scientific Title

Are gut hormone changes the reason why the long-limb gastric bypass is more effective than the standard limb gastric bypass in improving type 2 diabetes mellitus? A randomised controlled trial

Acronym

LONG LIMB

Study objectives

The aim of this study is to show that a new bariatric surgery, the long-limb gastric bypass, is more effective at treating diabetes in people with obesity than the standard-limb gastric bypass.

Ethics approval required

Old ethics approval format

Ethics approval(s)

West London & GTAC, 29/06/2015, ref: 15/LO/0813

Study design

Randomized; Double blind; Interventional; Design type: Treatment

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Topic: Diabetes; Subtopic: Type 2; Disease: Diabetic Control, Obesity

Interventions

Bariatric surgery, either the standard--limb or long--limb gastric bypass

Study Entry : Registration and one or more randomisations

Intervention Type

Procedure/Surgery

Primary outcome(s)

Current primary outcomes as of 29/04/2019:

Peak plasma GLP-1 concentration as measured by laboratory assays at baseline and at 2 weeks after intervention.

Previous primary outcomes as of 10/01/2017:

Mechanistic primary outcome: Peak plasma GLP-1 level as measured by laboratory assays at baseline and at the point of 20% weight loss.

Clinical primary outcome: Glycated haemoglobin (HbA1c) as measured by laboratory assays at baseline and 1 year.

Previous primary outcome:

Change in peak GLP-1 level; Timepoint(s): After the mixed meal tolerance test.

Key secondary outcome(s)

Current secondary outcome measures as of 29/04/2019:

1. Plasma levels of glucose, insulin, c-peptide, gut hormones, bile acids, FGF-19 and 21 after the mixed meal tolerance test are measured using laboratory assays at baseline, within 2 weeks and at the point of 20% weight loss
2. Rate of glucose appearance (Ra) and disposal (Rd) in the euglycaemic hyperinsulinaemic clamp is measured using mass spectroscopy/metry at baseline, within 2 weeks and at the point of 20% weight loss.
3. Faecal caloric content is measured using calorimetry at baseline, 20% weight loss and at 1 year
4. 4. Blood, urine and faecal microbial diversity and metabolomics are measured using mass spectroscopy/metry at baseline, within 2 weeks and at the point of 20% weight loss.
5. Total caloric intake and macronutrient composition is measured using dietary records at baseline and at 1 year
6. HbA1c is measured using by laboratory assays at baseline and 1 year
7. Total number of medications are measured using health records at baseline and 1 year
8. Rate of patients achieving diabetes remission is measured using HbA1c and number of medications at 1 year
9. Body weight is measured using scales at baseline and 1 year
10. Systolic, diastolic blood pressure and pulse are measured using a sphygmomanometer at baseline and 1 year
11. Serum fasting lipids are measured using laboratory assays at baseline and 1 year
12. Medical, surgical, nutritional and psychological complications are measured using health records at 1 year
13. Adverse events are measured using health records at 1 year
14. Glycated haemoglobin (HbA1c) as measured by laboratory assays at baseline and 1 year.

Previous secondary outcome measures:

1. Plasma levels of glucose, insulin, c-peptide, gut hormones, bile acids, FGF-19 and 21 after the mixed meal tolerance test are measured using laboratory assays at baseline, within 2 weeks and at the point of 20% weight loss
2. Rate of glucose appearance (Ra) and disposal (Rd) in the euglycaemic hyperinsulinaemic clamp is measured using mass spectroscopy/metry at baseline, within 2 weeks and at the point of 20% weight loss.
3. Faecal caloric content is measured using calorimetry at baseline, 20% weight loss and at 1 year
4. 4. Blood, urine and faecal microbial diversity and metabolomics are measured using mass spectroscopy/metry at baseline, within 2 weeks and at the point of 20% weight loss.

5. Total caloric intake and macronutrient composition is measured using dietary records at baseline and at 1 year
6. HbA1c is measured using by laboratory assays at baseline and 1 year
7. Total number of medications are measured using health records at baseline and 1 year
8. Rate of patients achieving diabetes remission is measured using HbA1c and number of medications at 1 year
9. Body weight is measured using scales at baseline and 1 year
10. Systolic, diastolic blood pressure and pulse are measured using a sphygmomanometer at baseline and 1 year
11. Serum fasting lipids are measured using laboratory assays at baseline and 1 year
12. Medical, surgical, nutritional and psychological complications are measured using health records at 1 year
13. Adverse events are measured using health records at 1 year

Completion date

14/08/2018

Eligibility

Key inclusion criteria

1. Both genders
2. Age 18-70 years
3. Type 2 diabetes mellitus
4. Obesity
5. HbA1c > 7.0%
6. On glucose-lowering medication

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Upper age limit

70 years

Sex

All

Total final enrolment

53

Key exclusion criteria

1. Contraindications to bariatric surgery
2. Type 1 diabetes
3. Pregnancy or breastfeeding
4. Recent blood donation

Date of first enrolment

31/07/2015

Date of final enrolment

01/02/2017

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Imperial College London, Hammersmith Hospital (lead centre)

Du Cane Road

London

United Kingdom

W12 0NN

Study participating centre

King's College London

Denmark Hill

London

United Kingdom

SE5 9RS

Sponsor information

Organisation

Imperial College London

ROR

<https://ror.org/041kmwe10>

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article		06/11/2020	23/09/2021	Yes	No
Results article		01/02/2021	18/08/2023	Yes	No
HRA research summary			28/06/2023	No	No